A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation

Ernie Anand,1 Lovisa Berggren,2 Claudia Deix,3 Ágoston Tóth,4 David P McDonnell5 1Neuroscience Medical Affairs – EU, Eli Lilly, Windlesham, United Kingdom; 2Global Statistical Sciences, Lilly Deutschland GmbH, Bad Homburg, Germany; 3Neuroscience, Eli Lilly Regional O...

Full description

Saved in:
Bibliographic Details
Main Authors: An, E, Berggren L, Deix C, Tóth Á, McDonnell DP
Format: article
Language:EN
Published: Dove Medical Press 2015
Subjects:
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Online Access:https://doaj.org/article/8d5b267f3f554425b7cf329f8a710e0c
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items